ArticlePloS one2026
Exploring the roles of genes associated with leukocyte transendothelial migration in liver cirrhosis development.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIndividuals with liver cirrhosis (LC) have an exceptionally high mortality rate. We aim to discover new biomarkers or new therapeutic targets for LC early diagnosis and treatment.
methodsThe human LC microarray datasets were obtained from the NCBI-GEO database. Firstly, differentially expressed analysis and WGCNA were performed to detect LC key genes. Protein-protein interaction (PPI) hubs revealed new regulatory mechanisms for LC-related genes. Functional enrichment and immune infiltration analyses were employed to reveal underlying mechanisms of LC progression. Then, key genes were further screened for constructing diagnostic nomogram for LC and predicting the prognosis of LC. CB-Dock-2 was employed to explore potential therapeutic agents for LC based on the identified key genes.Finally, immunohistochemistry was performed to detect the expression levels of the key genes in liver tissues from patients with liver cirrhosis and healthy controls.
resultsThe integrated LC dataset identified 749 LC key genes by intersecting WGCNA and differential expression analyses. PPI analysis identified 15 genes as key regulators in LC development, predominantly enriched in inflammatory and immune regulatory pathways. We conducted an in-depth analysis of two leukocyte transendothelial migration (LTM)-associated genes (MMP2 and ITGB2) among these 15 hub genes, revealing their involvement in the construction of the immune microenvironment in LC. A nomogram based on MMP2 and ITGB2 had favorable diagnostic performance for LC, and ITGB2 showed potential in predicting LC prognosis. Through molecular docking approaches, this study further identified several antioxidant and anti-inflammatory agents with therapeutic potential for LC. Immunohistochemical staining revealed significantly elevated protein levels of MMP2 and ITGB2 in liver tissues from cirrhotic patients compared to healthy controls.
conclusionsLTM-associated genes, namely MMP2 and ITGB2, are associated with LC and may represent candidate biomarkers or potential targets requiring further experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.